Tiziana Life Sciences plc ("Tiziana" or the "Company") Exercise of Warrants and Issue of Equity and Total Voting Rights London, New York, 22 June 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the "Company"

Warrants and Issue of Equity and Total Voting Rights

York, 22 June 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the "Company" or "Tiziana"),

a US and UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease

in oncology and immunology, today announces that it has allotted and issued 1,800,000 ordinary shares of 3 pence each

("New Ordinary Shares") credited as fully paid in respect of the exercise of 1,800,000 warrants at a price of 35

pence share, yielding 630,000 in cash proceeds for the Company.

has been made for the 1,800,000 New Ordinary Shares to be admitted to trading on AIM ("Admission"), and dealings are

expected to commence on or around 25 June 2020. The New Ordinary Shares will rank pari passu with the Company's existing Ordinary

with DTR 5.6.1, the Company notifies that as at the date of this announcement, it has a single class of shares in issue being Ordinary

Shares and that following the issue of the New Ordinary Shares to be issued in connection with the exercise of the warrants, the

total number of Ordinary Shares in issue will be 165,809,013. There are no Ordinary Shares held in treasury. Each Ordinary Share

entitles the holder to a single vote at general meetings of the Company.

165,809,013 Ordinary Shares may be used by shareholders (and others with notification obligations) as the denominator for the calculations

by which they will determine whether they are required to notify their interest in, or a change to their interest in, the Company

under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

Sciences plc is a dual listed (NASDAQ: TLSA & UK AIMS: TILS) biotechnology company that focuses on

the discovery and development of novel molecules to treat human diseases in oncology, inflammation and infectious diseases. In

addition to milciclib, the Company will be shortly initiating phase 2 studies with orally administered foralumab for Crohn's Disease

and nasally administered foralumab for progressive multiple sclerosis. Foralumab is the only fully human anti-CD3 monoclonal antibody

(mAb) in clinical development in the world. This phase II compound has potential application in a wide range of autoimmune and

inflammatory diseases, such as Crohn's Disease, multiple sclerosis, type-1 diabetes (T1D), inflammatory bowel disease (IBD), psoriasis

and rheumatoid arthritis, where modulation of a T-cell response is desirable. The company is accelerating development of anti-Interleukin

6 receptor (IL6R) mAb, a fully human monoclonal antibody for treatment of IL6-induced inflammation, especially for treatment of

announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

person who arranged the release of this information is Tiziano Lazzaretti, Chief Financial Officer of Tiziana.